Serum Immunoglobulin G (IgG) Subclasses in a Cohort of Systemic Sclerosis Patients
Abstract
:1. Introduction
2. Materials and Methods
2.1. Subjects
2.2. Clinical Assessment
2.3. Pulmonary Function Test
2.4. Chest High-Resolution Computed Tomography
2.5. Laboratory Assessment
2.6. Statistical Analysis
3. Results
3.1. Serum IgG and Subclasses—SSc Patients vs. HC
3.2. Serum IgG and Subclasses—Demographics
3.3. Serum IgG and Subclasses—Cutaneous and Articular Involvement
3.4. Serum IgG and Subclasses—Serology
3.5. Serum IgG and Subclasses—Microvascular Involvement
3.6. Serum IgG and Subclasses—DAI and DSS
3.7. Serum IgG and Subclasses—Cardiopulmonary Involvement
4. Discussion
Author Contributions
Funding
Institutional Review Board Statement
Informed Consent Statement
Data Availability Statement
Conflicts of Interest
References
- Gabrielli, A.; Avvedimento, E.V.; Krieg, T. Scleroderma. New Engl. J. Med. 2009, 360, 1989–2003. [Google Scholar] [CrossRef]
- Yoshizaki, A. Pathogenic roles of B lymphocytes in systemic sclerosis. Immunol. Lett. 2018, 195, 76–82. [Google Scholar] [CrossRef]
- Marrapodi, R.; Pellicano, C.; Radicchio, G.; Leodori, G.; Colantuono, S.; Iacolare, A.; Gigante, A.; Visentini, M.; Rosato, E. CD21low B cells in systemic sclerosis: A possible marker of vascular complications. Clin. Immunol. 2020, 213, 108364. [Google Scholar] [CrossRef]
- Gigante, A.; Pellicano, C.; Leodori, G.; Napodano, C.; Vantaggio, L.; Gulli, F.; Marino, M.; Visentini, M.; Rosato, E.; Basile, U. Serum and urine free light chains measurements in patients with systemic sclerosis: Novel biomarkers for disease activity. Clin. Exp. Immunol. 2021, 205, 135–141. [Google Scholar] [CrossRef]
- Martínez-Cordero, E.; Trejo, A.P.; León, D.E. IgM, IgG, and IgA anti-DNA topoisomerase I antibodies in systemic sclerosis. J. Clin. Lab. Anal. 2009, 23, 408–416. [Google Scholar] [CrossRef]
- Murthy, S.; Wannick, M.; Eleftheriadis, G.; Müller, A.; Luo, J.; Busch, H.; Dalmann, A.; Riemekasten, G.; Sadik, C.D. Immunoglobulin G of systemic sclerosis patients programs a pro-inflammatory and profibrotic phenotype in monocyte-like THP-1 cells. Rheumatology 2021, 60, 3012–3022. [Google Scholar] [CrossRef] [PubMed]
- Komura, K.; Yanaba, K.; Ogawa, F.; Shimizu, K.; Takehara, K.; Sato, S. Elevation of IgG levels is a serological indicator for pulmonary fibrosis in systemic sclerosis with anti-topoisomerase I antibodies and those with anticentromere antibody. Clin. Exp. Dermatol. 2008, 33, 329–332. [Google Scholar] [CrossRef] [PubMed]
- Napodano, C.; Marino, M.; Stefanile, A.; Pocino, K.; Scatena, R.; Gulli, F.; Rapaccini, G.L.; Noci, S.D.; Capozio, G.; Rigante, D.; et al. Immunological Role of IgG Subclasses. Immunol. Investig. 2021, 50, 427–444. [Google Scholar] [CrossRef] [PubMed]
- Zhang, H.; Li, P.; Wu, D.; Xu, D.; Hou, Y.; Wang, Q.; Li, M.; Li, Y.; Zeng, X.; Zhang, F.; et al. Serum IgG Subclasses in Autoimmune Diseases. Medicine 2015, 94, e387. [Google Scholar] [CrossRef]
- Van den Hoogen, F.; Khanna, D.; Fransen, J.; Johnson, S.R.; Baron, M.; Tyndall, A.; Matucci-Cerinic, M.; Naden, R.P.; Medsger, T.A., Jr.; Carreira, P.E.; et al. 2013 classification criteria for systemic sclerosis: An American college of rheumatology/European league against rheumatism collaborative initiative. Ann. Rheum. Dis. 2013, 72, 1747–1755. [Google Scholar] [CrossRef] [Green Version]
- Leroy, E.C.; Black, C.; Fleischmajer, R.; Jablonska, S.; Krieg, T.; Medsger, T.A., Jr.; Rowell, N.; Wollheim, F. Scleroderma (systemic sclerosis): Classification, subsets and pathogenesis. J. Rheumatol. 1988, 15, 202–205. [Google Scholar] [PubMed]
- Valentini, G.; Iudici, M.; Walker, U.A.; Jaeger, V.; Baron, M.; Carreira, P.E.; Czirják, L.; Denton, C.P.; Distler, O.; Hachulla, E.; et al. The European Scleroderma Trials and Research group (EUSTAR) task force for the development of revised activity criteria for systemic sclerosis: Derivation and validation of a preliminarily revised EUSTAR activity index. Ann. Rheum. Dis. 2017, 76, 270–276. [Google Scholar] [CrossRef] [PubMed]
- Medsger, T.A., Jr.; Silman, A.J.; Steen, V.D.; Black, C.M.; Akesson, A.; Bacon, P.A.; Harris, C.A.; Jablonska, S.; Jayson, M.I.; Jimenez, S.A.; et al. A disease severity scale for systemic sclerosis: Development and testing. J. Rheumatol. 1999, 26, 2159–2167. [Google Scholar]
- Cutolo, M.; Cerinic, M.M. Nailfold capillaroscopy and classification criteria for systemic sclerosis. Ann. Rheum. Dis. 2007, 25, 663–665. [Google Scholar]
- Amanzi, L.; Braschi, F.; Fiori, G.; Galluccio, F.; Miniati, I.; Guiducci, S.; Conforti, M.-L.; Kaloudi, O.; Nacci, F.; Sacu, O.; et al. Digital ulcers in scleroderma: Staging, characteristics and sub-setting through observation of 1614 digital lesions. Rheumatology 2010, 49, 1374–1382. [Google Scholar] [CrossRef] [PubMed]
- Miller, M.R.; Hankinson, J.; Brusasco, V.; Burgos, F.; Casaburi, R.; Coates, A.; Crapo, R.; Enright, P.; Van Der Grinten, C.P.M.; Gustafsson, P.; et al. ATS/ERS Task Force. Standardisation of spirometry. Eur. Respir. J. 2005, 26, 319–338. [Google Scholar] [CrossRef]
- Ferrazza, A.M.; Gigante, A.; Gasperini, M.L.; Ammendola, R.M.; Paone, G.; Carbone, I.; Rosato, E. Assessment of interstitial lung disease in systemic sclerosis using the quantitative CT algorithm CALIPER. Clin. Rheumatol. 2020, 39, 1537–1542. [Google Scholar] [CrossRef]
- Distler, O.; Highland, K.B.; Gahlemann, M.; Azuma, A.; Fischer, A.; Mayes, M.D.; Raghu, G.; Sauter, W.; Girard, M.; Alves, M.; et al. SENSCIS Trial Investigators. Nintedanib for Systemic Sclerosis–Associated Interstitial Lung Disease. New Engl. J. Med. 2019, 380, 2518–2528. [Google Scholar] [CrossRef] [PubMed]
- Blanco, F.; Kalsi, J.; Ravirajan, C.T.; Speight, P.; Bradwell, A.; Isenberg, D. IgG Subclasses in Systemic Lupus Erythematosus and Other Autoimmune Rheumatic Diseases. Lupus 1992, 1, 391–399. [Google Scholar] [CrossRef] [PubMed]
- Engelhart, S.; Glynn, R.J.; Schur, P.H. Disease associations with isolated elevations of each of the four IgG subclasses. Semin. Arthritis Rheum. 2017, 47, 276–280. [Google Scholar] [CrossRef]
- Liu, Y.; Li, J. Preferentially immunoglobulin (IgG) subclasses production in primary Sjögren’s syndrome patients. Clin. Chem. Lab. Med. 2012, 50, 345–349. [Google Scholar] [CrossRef]
- Haddad, A.; Thavaneswaran, A.; Abji, F.; Pellett, F.; Chandran, V.; Wither, J.E.; Gladman, D.D. Immunoglobulin G Subclass Analysis in Psoriatic Arthritis. J. Rheumatol. 2014, 41, 2421–2424. [Google Scholar] [CrossRef]
- Schroeder, H.W., Jr.; Cavacini, L. Structure and function of immunoglobulins. J. Allergy Clin. Immunol. 2010, 125 (Suppl. S2), S41–S52. [Google Scholar] [CrossRef] [PubMed]
- Devey, M.E.; Lee, S.R.; Page, S.L.; Feldman, R.; Isenberg, D.A. Serial studies of the IgG subclass and functional affinity of DNA antibodies in systemic lupus erythematosus. J. Autoimmun. 1988, 1, 483–494. [Google Scholar] [CrossRef] [PubMed]
- Elhai, M.; Guerini, H.; Bazeli, R.; Avouac, J.; Freire, V.; Drapé, J.-L.; Kahan, A.; Allanore, Y. Ultrasonographic hand features in systemic sclerosis and correlates with clinical, biological and radiographic findings. Arthritis Care Res. 2012, 64, 1244–1249. [Google Scholar] [CrossRef]
- Chepy, A.; Vivier, S.; Bray, F.; Ternynck, C.; Meneboo, J.-P.; Figeac, M.; Filiot, A.; Guilbert, L.; Jendoubi, M.; Rolando, C.; et al. Effects of Immunoglobulins G From Systemic Sclerosis Patients in Normal Dermal Fibroblasts: A Multi-Omics Study. Front. Immunol. 2022, 13, 904631. [Google Scholar] [CrossRef] [PubMed]
- Silver, R.M.; Metcalf, J.F.; Stanley, J.H.; Leroy, E.C. Interstitial lung disease in scleroderma analysis by bronchoalveolar lavage. Arthritis Rheum. 1984, 27, 1254–1262. [Google Scholar] [CrossRef]
- Basile, U.; Gulli, F.; Gragnani, L.; Fognani, E.; Napodano, C.; Pocino, K.; Zignego, A.L.; Rapaccini, G.L. IgG3 subclass: A possible trigger of mixed cryoglobulin cascade in hepatitis C virus chronic infection. Dig. Liver Dis. 2017, 49, 1233–1239. [Google Scholar] [CrossRef] [PubMed]
- Randone, S.B.; Guiducci, S.; Cerinic, M.M. Systemic sclerosis and infections. Autoimmun. Rev. 2008, 8, 36–40. [Google Scholar] [CrossRef]
- Yurovsky, V.V.; Wigley, F.M.; Wise, R.A.; White, B. Skewing of the CDS + T-cell repertoire in the lungs of patients with systemic sclerosis. Hum. Immunol. 1996, 48, 84–97. [Google Scholar] [CrossRef] [PubMed]
- Arnson, Y.; Amital, H.; Guiducci, S.; Matucci-Cerinic, M.; Valentini, G.; Barzilai, O.; Maya, R.; Shoenfeld, Y. The Role of Infections in the Immunopathogensis of Systemic Sclerosis-Evidence from Serological Studies. Ann. New York Acad. Sci. 2009, 1173, 627–632. [Google Scholar] [CrossRef] [PubMed]
- Servaas, N.; Zaaraoui-Boutahar, F.; Wichers, C.; Ottria, A.; Chouri, E.; Affandi, A.; Silva-Cardoso, S.; van der Kroef, M.; Carvalheiro, T.; van Wijk, F.; et al. Longitudinal analysis of T-cell receptor repertoires reveals persistence of antigen-driven CD4+ and CD8+ T-cell clusters in systemic sclerosis. J. Autoimmun. 2021, 117, 102574. [Google Scholar] [CrossRef] [PubMed]
Age, years, median and IQR | 55 (45–59) |
Female, n (%) | 57 (85.1) |
dcSSc, n (%) | 38 (56.7) |
Disease duration, years, median, and IQR | 10 (6–15) |
mRSS, median and IQR | 12 (7–17) |
Autoantibodies | |
Anti-topoisomerase I, n (%) | 30 (44.8) |
Anti-centromere, n (%) | 13 (19.4) |
Anti-RNApolymerase III, n (%) | 2 (3) |
None, n (%) | 22 (32.8) |
NVC | |
Early, n (%) | 12 (17.9) |
Active, n (%) | 24 (35.8) |
Late, n (%) | 31 (46.3) |
DAI, median and IQR | 1.67 (0.84–3.75) |
DSS, median and IQR | 6 (4–8) |
Digital ulcers, n (%) | 11 (16.4) |
sPAP, mmHg, median and IQR | 28 (25–30) |
DLco, % of predicted, median and IQR | 77 (65–84) |
DLco ≤ 60% of predicted, n (%) | 11 (16.4) |
ILD, n (%) | 16 (23.9) |
SSc | HC | p | |
---|---|---|---|
IgG, g/l, median and IQR | 9.88 (8.18–11.42) | 12.09 (10.24–13.54) | <0.001 |
IgG1, g/l, median and IQR | 5.09 (4.25–6.38) | 6.03 (5.39–7.90) | <0.001 |
IgG2, g/l, median and IQR | 3.58 (2.87–4.64) | 4 (2.62–4.90) | >0.05 |
IgG3, g/l, median and IQR | 0.59 (0.40–0.77) | 0.80 (0.46–1) | <0.05 |
IgG4, g/l, median and IQR | 0.24 (0.12–0.49) | 0.32 (0.20–0.51) | >0.05 |
IgG1/IgG, %, median and IQR | 0.53 (0.48–0.61) | 0.56 (0.50–0.60) | >0.05 |
IgG2/IgG, %, median and IQR | 0.38 (0.30–0.43) | 0.35 (0.27–0.40) | >0.05 |
IgG3/IgG, %, median and IQR | 0.06 (0.04–0.08) | 0.06 (0.04–0.08) | >0.05 |
IgG4/IgG, %, median and IQR | 0.03 (0.01–0.05) | 0.03 (0.02–0.05) | >0.05 |
Female SSc (n = 57) | Male SSc (n = 10) | p | |
---|---|---|---|
IgG, g/l, median and IQR | 10.04 (8.8–11.42) | 9.21 (6.6–9.94) | >0.05 |
IgG1, g/l, median and IQR | 5.09 (4.29–6.38) | 5.04 (3.79–5.57) | >0.05 |
IgG2, g/l, median and IQR | 3.66 (3.05–4.64) | 2.57 (1.98–3.77) | >0.05 |
IgG3, g/l, median and IQR | 0.58 (0.41–0.67) | 0.77 (0.28–1.19) | >0.05 |
IgG4, g/l, median and IQR | 0.23 (0.15–0.44) | 0.43 (0.07–0.65) | >0.05 |
dcSSc (n = 38) | lcSSc (n = 29) | p | |
---|---|---|---|
IgG, g/l, median and IQR | 10.22 (8.99–11.65) | 9.12 (7.71–10.43) | >0.05 |
IgG1, g/l, median and IQR | 5.10 (4.30–6.38) | 4.97 (4.10–6.02) | >0.05 |
IgG2, g/l, median and IQR | 3.83 (3.13–5.08) | 3.10 (2.41–3.87) | <0.05 |
IgG3, g/l, median and IQR | 0.60 (0.43–0.77) | 0.53 (0.39–0.82) | >0.05 |
IgG4, g/l, median and IQR | 0.28 (0.11–0.49) | 0.19 (0.15–0.44) | >0.05 |
Centromere (n = 13) | None (n = 22) | RNApolymerase III (n = 2) | Topoisomerase I (n = 30) | p | |
---|---|---|---|---|---|
IgG, g/l, median and IQR | 8.8 (7.48–10.04) | 9.91 (8.88–11.65) | 14.78 (11.28–18.28) | 10.05 (8.63–11.42) | >0.05 |
IgG1, g/l, median and IQR | 4.59 (4.1–5.51) | 5.63 (4.58–6.77) | 7.63 (7.1–8.17) | 4.78 (4.23–5.85) | >0.05 |
IgG2, g/l, median and IQR | 3.1 (1.91–3.87) | 3.14 (2.74–4.39) | 5.56 (3.32–7.8) | 3.88 (3.13–4.77) | >0.05 |
IgG3, g/l, median and IQR | 0.55 (0.3–0.63) | 0.53 (0.4–1.06) | 0.94 (0.63–1.25) | 0.59 (0.42–0.69) | >0.05 |
IgG4, g/l, median and IQR | 0.16 (0.15–0.39) | 0.24 (0.15–0.51) | 0.65 (0.24–1.06) | 0.27 (0.11–0.45) | >0.05 |
DLco ≤ 60% of Predicted | ILD | |||
---|---|---|---|---|
OR (CI 95%) | p | OR (CI 95%) | p | |
Age, years | 1.032 (0.960–1.110) | >0.05 | 1.036 (0.958–1.211) | >0.05 |
Disease duration, years | 0.965 (0.867–1.074) | >0.05 | 1 (0.930–1.076) | >0.05 |
mRSS | 1.063 (0.971–1.163) | >0.05 | 1.124 (1.019–1.240) | <0.05 |
Anti-topoisomerase I | 0.651 (0.115–3.666) | >0.05 | 0.060 (0.007–0.535) | <0.05 |
IgG3, g/l | 9.734 (1.312–72.221) | <0.05 | 14.062 (1.352–146.229) | <0.05 |
Disclaimer/Publisher’s Note: The statements, opinions and data contained in all publications are solely those of the individual author(s) and contributor(s) and not of MDPI and/or the editor(s). MDPI and/or the editor(s) disclaim responsibility for any injury to people or property resulting from any ideas, methods, instructions or products referred to in the content. |
© 2023 by the authors. Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (https://creativecommons.org/licenses/by/4.0/).
Share and Cite
Pellicano, C.; Colalillo, A.; Cusano, G.; Palladino, A.; Pellegrini, M.; Callà, C.A.M.; Mazzuccato, G.; Carnazzo, V.; Pignalosa, S.; Di Biase, L.; et al. Serum Immunoglobulin G (IgG) Subclasses in a Cohort of Systemic Sclerosis Patients. J. Pers. Med. 2023, 13, 309. https://doi.org/10.3390/jpm13020309
Pellicano C, Colalillo A, Cusano G, Palladino A, Pellegrini M, Callà CAM, Mazzuccato G, Carnazzo V, Pignalosa S, Di Biase L, et al. Serum Immunoglobulin G (IgG) Subclasses in a Cohort of Systemic Sclerosis Patients. Journal of Personalized Medicine. 2023; 13(2):309. https://doi.org/10.3390/jpm13020309
Chicago/Turabian StylePellicano, Chiara, Amalia Colalillo, Giuseppina Cusano, Andrea Palladino, Marica Pellegrini, Cinzia Anna Maria Callà, Giorgia Mazzuccato, Valeria Carnazzo, Stefano Pignalosa, Luigi Di Biase, and et al. 2023. "Serum Immunoglobulin G (IgG) Subclasses in a Cohort of Systemic Sclerosis Patients" Journal of Personalized Medicine 13, no. 2: 309. https://doi.org/10.3390/jpm13020309
APA StylePellicano, C., Colalillo, A., Cusano, G., Palladino, A., Pellegrini, M., Callà, C. A. M., Mazzuccato, G., Carnazzo, V., Pignalosa, S., Di Biase, L., Marino, M., Basile, U., & Rosato, E. (2023). Serum Immunoglobulin G (IgG) Subclasses in a Cohort of Systemic Sclerosis Patients. Journal of Personalized Medicine, 13(2), 309. https://doi.org/10.3390/jpm13020309